Fibrosis and inflammation promote atrial fibrillation (AF) and worsen its clinical outcome. The underlying molecular mechanisms, that are relevant for effective antifibrotic drug development, are still under debate. This study deciphers a novel mechanistic interplay between polo-like kinase 2 (PLK2) and the pro-inflammatory cytokine osteopontin (OPN) in the pathogenesis of atrial fibrosis. Compared to sinus rhythm (SR) controls, right atrial appendages and isolated right atrial fibroblasts from AF patients showed downregulation of PLK2 mRNA and protein levels, which were accompanied by remarkable hypoxia-sensitive DNA-methylation of the PLK2 promotor. In an experimental setting, both, genetic deletion and pharmacological inhibition of PLK2 induced myofibroblast differentiation and reduced fibroblast proliferation.
Introduction
Atrial fibrillation (AF) is the most prevalent arrhythmia in the clinical routine. Reoccurring AF episodes lead to marked changes in the cardiac tissue architecture (Harada et al, 2015; Hadi et al, 2010; Boos et al, 2006) and contribute to morbidity and mortality. Current pharmacological therapies aim predominantly at directly suppressing arrhythmia by ion channel blockade. However, these approaches tend to be insufficient and tend to produce detrimental side effects that include arrhythmias (Heijman et al, 2018) . Recently, there is paradigm change in AF pathophysiology pointing to AF being a (systemic) inflammatory disease that is not confined to the atria. Therefore, we chose to examine a specific cell population, the cardiac fibroblasts, that are involved in inflammation and fibrosis. The approach to target specific inflammatory mediators and fibrosis-associated genes in fibroblasts may constitute a novel approach to prevent or treat the progression of AF (Rudolph et al, 2010) .
Any kind of cardiac injury or disorder can activate fibroblasts leading to myofibroblast differentiation (Tallquist & Molkentin, 2017; Nattel et al, 2008) . Once activated, myofibroblasts gain size, express orderly arranged filaments of alpha smooth muscle actin (αSMA) and become highly secretory, resulting in deposition of interstitial collagen as well as local enrichment of cytokines and other inflammation mediators (Tallquist & Molkentin, 2017; Baum & Duffy, 2011) . There is strong phenomenological evidence for altered fibroblast function in persistent AF in terms of increased myofibroblast differentiation and reduced fibroblast proliferation (Poulet et al, 2016) . The underlying molecular mechanisms still remain widely elusive.
A number of inflammation mediators like interleukins 2, 6, 8, and 10, C-reactive protein, TNFα or matrix metalloproteinases 1 and 2 as well as osteopontin (OPN) have been associated with the pathogenesis and progression of AF. They are considered to induce the fibrotic and proarrhythmic substrate in AF patients (Calvo et al, 2018; Chung et al, 2001; Watanabe et al, 2005; Vílchez et al, 2014) . Several of those biomarkers have been found in both cardiac tissue biopsies and the peripheral blood of AF patients (Harada et al, 2015; Vílchez et al, 2014) .
Recent studies indicated promising potential of OPN as a therapeutic target in inflammationassociated cardiac disease (Zhao et al, 2016) . OPN is a glycoprotein of the extracellular matrix secreted by macrophages, T-cells and fibroblasts in the heart. Latest studies have demonstrated cytokine-like functions of OPN, mediating inflammation, heart remodeling processes, fibrosis and increasing the risk of atherosclerosis and heart failure (Zhao et al, 2016; İçer & Gezmen-Karadağ, 2018; López et al, 2013; Rubiś et al, 2018) .
Recent research in our laboratory focused on differentially regulated genes in fibroblasts isolated from patients with persistent AF. An Affymetrix ® microarray (Poulet et al, 2016) revealed negative regulation of polo-like kinase 2 (PLK2) transcripts. PLK2 is a serinethreonine kinase that regulates cell cycle progression by centriole duplication and it is strongly associated with cell proliferation, mitochondrial respiration and apoptosis (Mochizuki et al, 2017; Li et al, 2014; Ma et al, 2003, 2) . Published data suggest that PLK2 suppression may induce cellular senescence (Deng et al, 2017) , a condition in which cells stop to proliferate (Coppé et al, 2008) .
Thus, the objective of the current study was to clarify the (patho)physiological role of PLK2 in fibrosis, inflammation and the pathogenesis of permanent AF. we provide first evidence for a molecular link of dysregulated PLK2 expression and altered OPN secretion in pathological fibrosis.
Results

PLK2 expression is reduced in AF.
Based on lower PLK2 mRNA expression in AF fibroblasts in the Affymetrix ® microarray (Poulet et al, 2016) , we confirmed a ~50% downregulation of PLK2 mRNA abundance in fibroblasts isolated from AF patients as determined by quantitative real-time PCR (Figure 1 a) . Furthermore, PLK2 protein expression was significantly reduced in human right atrial tissue samples from AF patients in comparison to those from patients with sinus rhythm (SR) (Figure 1 b and c) as determined by western blotting. Previous studies in non-cardiac tissues (Syed et al, 2006; Benetatos et al, 2011) have shown that PLK2 expression is strongly regulated by promoter hypermethylation. Therefore, we performed methylationspecific PCR for the PLK2 promoter, which was positive in 6 out of 13 AF samples, while there was no detectable methylation of the PLK2 promoter in any of the SR samples (n = 11) tested in our study ( Figure 2 a and b ). This suggests that AF pathogenies and/ or progression may involve epigenetic modifications affecting the PLK2 promoter. To test this hypothesis, we exposed fibroblasts to chronic hypoxia (1% O2) treatment for 24, 72 and 96 h (Figure 2 c and d) since tissue hypoxia is present in AF and known to induce several epigenetic alterations (Gramley et al, 2010; Watson et al, 2014) . After 24 h we found a 3.2-fold downregulation of PLK2 mRNA expression (Figure 2 c). Methylation of the PLK2 promoter was detectable after 96 h of chronic hypoxia treatment. As an additional positive control, cells were treated with 0.25 mM Dimethyloxaloylglycine (DMOG) which is an inhibitor of PHD finger protein (PHF) and factor inhibiting HIF (FIH-1) mimicking hypoxia by upregulation of hypoxia-inducible factor (HIF-1α) (Ayrapetov et al, 2011) . 96 h DMOG treatment led to clearly detectable PLK2 promoter methylation.
Inhibition and loss of PLK2 induces myofibroblast differentiation and abolishes
fibroblast proliferation. Next, we studied the effects of pharmacological PLK2 inhibition (TC-S 7005, 1 µM, 7±1 days) in primary human SR fibroblasts and the consequences of genetic PLK2 deletion (PLK2 KO (Inglis et al, 2009) Inhibition and loss of PLK2 induce cellular senescence. Expression of senescenceassociated β-galactosidase (SABG) is a hallmark of cellular senescence (Collado et al, 2007; Zhu et al, 2013) . Hence, a screening assay of the SABG activity was performed with primary human SR fibroblasts treated with TC-S 7005 (Figure 4 Loss of PLK2 promotes de novo secretion of osteopontin. Based on the finding that PLK2 inhibition as well as KO initiated myofibroblast differentiation and senescence induction, we studied the secretory phenotype of PLK2 KO fibroblasts using mass spectrometry secretome analysis of the cell culture media (Coppé et al, 2008) . We found particularly striking de novo secretion of OPN in PLK2 KO fibroblasts (Figure 5 a, supplemental table 4) . Notably, OPN was also elevated in right atrial appendages from AF patients compared to SR (Figure 5 b) .
Consequently, we assessed levels of OPN in the peripheral blood of AF patients. To test if the severity of fibrosis in AF patients is directly correlated with serum OPN levels we compared AF patients with and without low voltage zones in the left atrium found during their electrophysiological study. Low voltage zones constitute the electrophysiological surrogate of atrial fibrosis (Verma et al, 2005) . Both AF groups (without and with fibrosis) displayed elevated OPN levels in the peripheral blood (+1.7-fold in AF without fibrosis) compared to the SR group. Loss of PLK2 activates the p42/44 MAPK pathway via RasGRF2 to increase OPN expression. To propose a mechanistic link between lower PLK2 expression and higher OPN secretion of cardiac fibroblasts, we focused on the Ras -p42/44 MAPK pathway which was shown to act downstream of PLK2 as well as upstream of OPN (Hickey et al, 2005; El-Tanani et al, 2006) . Indeed, inhibition of PLK2 with TC-S 7005 for 72h resulted in 2-fold higher expression of RasGRF2 in cardiac fibroblasts indicating that RasGRF2 protein abundance is regulated by PLK2 (Figure 7 a). We also found higher abundance of p42/44 MAPK (ERK1/2) in cardiac fibroblasts after TC-S 7005 pretreatment, which acts downstream of RasGRF2 and the Ras pathway (Thomas et al, 1992; Lee et al, 2011b Lee et al, , 2011a (Figure 7 b, c). Several studies have shown that the Ras-pathway and p42/44 MAPK are mediators of OPN transcription (Hickey et al, 2005; El-Tanani et al, 2006; Xie et al, 2004) . Accordingly, after inhibition of PLK2 we found higher OPN expression (p = 0.05) in fibroblasts (Figure 7 d) . Representative western blots are provided in Figure 7 eg. Thus, we provide evidence that reduced PLK2 expression in AF augments RasGRF2 and enhances expression of p42/44 MAPK which may stimulate the transcription of OPN and its secretion.
Discussion
This study demonstrates that dysregulated PLK2 contributes to fibroblast activation, subsequent myofibroblast transition and enhanced secretion of OPN. Moreover, PLK2 expression is sensitive to established AF-dependent stress conditions such as hypoxia. Thus, its druggable downstream effectors (Ras/ MAPK/ OPN) may constitute valuable targets for antifibrotic and/or anti-inflammatory interventions to abolish pathological atrial fibrosis in patients with AF ( Figure 8 ).
Hypoxia has already been linked to global DNA methylation, contributing to fibrosis development in the lung by inducing myofibroblast differentiation and the expression of fibrosis markers (Robinson et al, 2012) . We observed pronounced PLK2 downregulation already after 24h of hypoxia treatment (1% O2) (Figure 2 c) but increased PLK2 promoter methylation was not detectable until 4 days of hypoxia treatment. This is in line with a recent publication which identified 4 days of hypoxia as minimum to reach the threshold for detection of DNA methylation in human fibroblasts (Robinson et al, 2012) .Our finding of aberrant methylation in AF patients is of clinical interest, since DNA methylation is reversible (Plumb et al, 2000) : In a mouse model of kidney fibrosis, demethylation of the RASAL1 gene by application of the DNA methyl transferase inhibitor 5-azacytidine significantly attenuated pathological fibrosis (Bechtel et al, 2010) . For PLK2, a similar approach could be feasible to counteract fibroblast activation and fibrotic remodeling in AF.
Furthermore, we provide a link between PLK2 and the fate of cardiac fibroblasts. We demonstrate that PLK2 inhibition or KO induce myofibroblast differentiation and consequently reduce cell proliferation in cardiac fibroblasts. This finding fits well to a recent study showing PLK2 as a key regulator for proliferation and differentiation in cardiac progenitor cells (Mochizuki et al, 2017) . Moreover, primary human cardiac fibroblasts from AF patients were shown to differentiate into myofibroblasts to a greater extent and to proliferate less compared to SR controls (Poulet et al, 2016) . Activated myofibroblasts are highly active secretory cells that substantially contribute to fibrosis in the diseased heart (Tallquist & Molkentin, 2017) .
Accordingly, we demonstrated vast interstitial fibrosis areas in the PLK2 knockout mice by histological analysis. Fibrosis is considered then to worsen cardiac performance by increasing wall stiffness leading to reduced diastolic filling, increased heart rate and consequently increased oxygen consumption. Moreover, fibrosis underlies the arrhythmogenic substrate fostering cardiac arrhythmia like AF ( Figure 8 ). Our data suggest that reduced PLK2 expression in AF is a molecular trigger for enhanced myofibroblast differentiation and lower proliferation in AF.
Importantly, beside enhanced myofibroblast differentiation inhibition of PLK2 led to accelerated cellular senescence in primary human atrial fibroblasts. This finding is consistent with a study showing that transcriptional inhibition of PLK2 by miRNA-146a induced senescence in bone marrow cells (Deng et al, 2017) . There is growing evidence that increased proportions of senescent fibroblasts can contribute to the disruption of regular tissue architecture (Krtolica et al, 2001; Parrinello et al, 2005) . Moreover, cardiac senescence has been shown to play an important role in diabetic cardiomyopathy and fibrosis in a mouse model (Gu et al, 2018) . In this scenario, we propose that PKL2 is a novel regulator of cardiac fibroblast senescence, which may additionally contribute to the pathogeneses of AF patients.
Myofibroblasts and senescent fibroblasts are known to secrete a plethora of extracellular matrix proteins and inflammatory cytokines (Baum & Duffy, 2011; Childs et al, 2015) . In PLK2 KO fibroblast culture media, discovery proteomics revealed de novo secretion of the inflammatory cytokine-like protein OPN which has been shown to induce inflammation, arteriosclerosis and cardiomyopathy (Zhao et al, 2016) . In AF patients, OPN was elevated on tissue-level in right atria as well as systemically in the peripheral blood in comparison to SR controls. OPN levels in the peripheral blood of patients have been investigated as prognostic biomarker to predict the AF recurrence after cryoballoon catheter ablation (Güneş et al, 2017) .
Additionally, high OPN plasma levels correlate with ventricular tachycardia and fibrillation in heart failure patients (Francia et al, 2014) . Our data indicate that OPN is a PLK2-dependent systemic-inflammatory component of AF, which correlates with concomitant cardiac fibrosis.
Finally, we propose a mechanistic link between PLK2 suppression and enhanced OPN secretion. We found that RasGRF2 is downstream regulated by PLK2 and that inhibition of PLK2 leads to p42/44 MAPK (ERK1/2) accumulation in cardiac fibroblasts. PLK2
phosphorylates RasGRF1 leading to its proteasomal degradation and thereby inhibits the Ras pathway (Lee et al, 2011a) . Moreover, the Ras-pathway and p42/44 MAPK have been shown to modulate OPN transcription (Hickey et al, 2005; El-Tanani et al, 2006; Xie et al, 2004) .
Reduced phosphorylation-dependent degradation of RasGRF2 by inhibition of PLK2 may well underlie our findings in the present study. RasGRF2 on the other hand is known to stimulate the Ras pathway resulting in higher expression of p42/44 MAPK which then may stimulate OPN expression and secretion. To study whether our findings reflect aberrant gene expression, RNA sequencing with subsequent bioinformatical analysis was performed in PLK2 WT and KO fibroblasts. Surprisingly, there were no significantly altered mRNA expression patterns between PLK2 WT and KO (except for missing PLK2 expression in the KO group) (Supplemental figure 2). This finding thus indicates that loss of PLK2 affects mainly protein expression on a post transcriptional level. Our hypothesis of OPN being the key mediator of PLK2-dependent inflammation and fibrosis in AF could be of particular clinical relevance because of existing and approved compounds counteracting OPN (Geschka et al, 2011) , e.g. soluble guanylate cyclase stimulators like riociguat which ameliorate cardiac fibrosis and attenuate OPN release (Geschka et al, 2011; Sandner et al, 2017) . These small molecules could be a starting point to modulate the PLK2-OPN axis in treatment and prevention of AF.
Conclusions and Clinical Implications
AF, the most relevant cardiac arrhythmia in humans, is a complex, systemic inflammatory disorder with strikingly increasing numbers of afflicted patients. Yet, only little is known about the underlying molecular pathways. Our work demonstrates that the PLK2-OPN axis in atrial fibroblasts contributes to fibroblast dysfunction and pathological fibrosis in permanent AF. To our knowledge, this is the first study to propose a novel pathophysiological role for the family of polo-like kinases in AF pathophysiology. Here we provide a mechanistic link between reduced PLK2 expression in AF and concomitant OPN release. Our results suggest that modulation of PLK2 activity and/or inhibition of OPN release could ameliorate pathological remodeling in AF. Whenever excess material remained, the tissue was frozen and stored in liquid nitrogen.
Methods
Peripheral blood samples from AF patients who would undergo ablation of pulmonary veins
were collected prior to the intervention in EDTA-tubes. Low voltage zones were assessed by electrophysiological mapping of the left atrium and defined as bipolar voltage < 0.5 mV. Blood samples were kept at 4° C for a maximum of 1 h. The tubes were then centrifuged for 10 min at 1000 g at 4° C. Subsequently, the plasma was transferred carefully into 500 µl Eppendorf tubes and stored at -80° C until analysis. Corresponding patient data can be found in supplemental tables 1, 2 and 3. PLK2 WT and KO mice. PLK2 WT and KO mice are commercially available via The Jackson Laboratory (Bar Harbor, USA) (129S.B6N-Plk2 tm1Elan /J, stock number: 017001 Plk2 KO). The mouse model has previously been used to study the alpha-synuclein phosphorylation at serine 129 in the central nervous system (Inglis et al, 2009 ). The animal study was approved by the institutional bioethics committee (T 2014/5; TVA 25/2017).
Cell isolation and culture. Primary human right atrial fibroblasts were isolated via outgrowth method from right atrial appendage biopsies as published previously (Poulet et al, 2016) . Cells were kept in a humidified surrounding at 37°C and 5 % CO2. In order to generate hypoxic conditions (1 % O2) cells were cultured in a hypoxia incubator chamber (Coy Laboratory Products Inc, Grass Lake, USA) for 24 up to 72 h.
Immunocytofluorescence. In order to perform immunocytoflorescence experiments, fibroblasts were seeded on 1 cm glass cover slips and grown for 7±1 days until they reached approximately 80 % of optical confluence. Cells were then washed with cold PBS, fixed in 4 % PFA for 15 min at RT, washed and subsequently permeabilised using Triton X. After blocking with FCS the cover slips were incubated with a mixture of primary antibody against αSMA (Sigma-Aldrich, St. Louis, Missouri, USA) and 4′,6-Diamidin-2-phenylindol (DAPI) (1:200;
A5228, Sigma-Aldrich, St. Louis, Missouri, USA) for 1 h in a dark, humidified surrounding at RT. After washing, the secondary antibody Alexa-Fluor 448 (Abcam, Cambridge, UK) was applied for 1 h in a dark, humidified surrounding at RT. The samples were kept in the dark until fluorescence images were obtained with a Zeiss LSM-510 confocal microscope.
Histological analysis. For histological analysis, a mid-ventricular section of the heart was excised and fixed in 4% PFA for 24 h before dehydration using an ethanol gradient.
Subsequently the samples were embedded in paraffin, sectioned at 3 µm thickness and stained with either Masson Trichrome or Sirius red (Sigma-Aldrich, St. Louis, Missouri, USA).
Images were acquired using the Keyence BZ-X710 All-in-One Fluorescence Microscope (Keyence Corporation of America, Itasca, USA). β-galactosidase staining assay for senescence detection. Fibroblasts were plated on 6well plates at densities of 2.5*10 4 cells/ well and kept in culture for 7 days. Subsequently, cells were fixed with 4 % formaldehyde for 15 min at room temperature (RT) and the senescence staining was done. A standard senescence detection kit (senescence associated βgalactosidase (SABG) staining) was used according to the manufacturer's instructions Methylation-specific PCR. The methylation-specific PCR was performed as published by Syed et al., 2006 and Robinson et al., 2017 (Syed et al, 2006 Benetatos et al, 2011) . Genomic DNA (gDNA)was isolated using the PureLink Genomic DNA Extraction kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Purified gDNA was subsequently bisulfiteconverted using the EZ DNA starter kit according to the manufacturer's instructions. The following PCR protocol was designed according to the suggestions of ZYMO Research. For unmethylated samples 36 cycles were run and for detection of DNA methylation 38 runs, respectively. For electrophoresis, the PCR products were then applied to a 2 % agarose gel containing HD green (INTAS Science Imaging Instruments GmbH, Göttingen, Germany).
Visualization of gel bands was achieved with a Fusion FX (Peqlab Biotechnologie GmbH,
Erlangen, Germany) development device. The following primers as published by Syed et al. (Syed et al, 2006) were used for methylation-specific PCR: and validated with the following filter: peptide probability > 95% and protein probability > 99% with minimum 2 peptides. Total spectra count was used as quantitative value.
RNA sequencing and bioinformatics. The RNA sequencing and subsequent bioinformatical analysis was done as published by Schott et al (Schott et al, 2017) . For Whole-Transcriptome Sequencing (RNA-Seq), 1.5x 10 6 murine cardiac PLK2 WT and KO fibroblasts were seeded in T-25 flasks and cultured until optical confluency. Subsequently, cells were harvested for RNA extraction (as described above). For library preparation the TruSeq Stranded Total RNA Library Prep Kit (Illumina, San Diego, USA) was used according to the manufacturer's instructions, starting with 1 μg total RNA. All barcoded libraries were pooled and sequenced 2x75bp paired-end on an Illumina NextSeq500 platform to obtain a minimum of 10 Mio reads per sample. Raw reads were converted from bcl to fastq format using bcl2fastq, quality trimmed with trimmomatic (Bolger et al, 2014) and then aligned against the Ensembl 92 mouse genome using STAR (Dobin et al, 2013) in a 2-pass mapping mode. Read counts of all annotated genes were extracted from the alignments using feature Counts method of the Rsubread package (Liao et al, 2013) and genes with 0 counts for all samples were discarded.
DESeq2 (Love et al, 2014 ) was used to find differentially expressed genes using standard parameters. Only genes with multiple testing adjusted p-values < 0.05 were considered significant. Clustering was done with Euclidean distance and complete linkage using Consequently, there is a need to define targets for therapies that limit the debilitating consequences of atrial fibrillation.
Results. We identified PLK 2 as an epigenetically regulated kinase involved in the pathophysiology of fibrosis in atrial fibrillation. In atrial tissue samples from patients with chronic atrial fibrillation, PLK 2 was nearly 50 % downregulated by hypoxia-induced promoter methylation. In vitro, loss of PLK 2 led to strikingly reduced fibroblast proliferation, increased myofibroblast differentiation and enhanced senescence induction. Additionally, we found that genetic knockout of PLK2 resulted in de novo secretion of the inflammatory cytokine-like protein osteopontin. Accordingly, we measured ex vivo elevated osteopontin in both heart tissue and the peripheral blood of atrial fibrillation patients and healthy sinus rhythm controls.
We identified the Ras-ERK1/2 signaling pathway to be the potential link between reduced expression of PLK2 and elevated osteopontin secretion. 
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